uniQure (QURE) Competitors

uniQure logo
$21.88 -1.93 (-8.11%)
Closing price 04:00 PM Eastern
Extended Trading
$21.84 -0.04 (-0.20%)
As of 07:54 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

QURE vs. KOD, ARWR, IBRX, LGND, and CGON

Should you buy uniQure stock or one of its competitors? uniQure's main competitors and comparable companies include Kodiak Sciences (KOD), Arrowhead Pharmaceuticals (ARWR), ImmunityBio (IBRX), Ligand Pharmaceuticals (LGND), and CG Oncology (CGON). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does uniQure compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, dividends, analyst recommendations, media sentiment, profitability, risk, institutional ownership and valuation.

Kodiak Sciences has a beta of 2.02, suggesting that its share price is 102% more volatile than the broader market. Comparatively, uniQure has a beta of 1.14, suggesting that its share price is 14% more volatile than the broader market.

uniQure has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A
uniQure$16.10M103.73-$198.97M-$3.51N/A

89.1% of Kodiak Sciences shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 44.4% of Kodiak Sciences shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Kodiak Sciences had 6 more articles in the media than uniQure. MarketBeat recorded 13 mentions for Kodiak Sciences and 7 mentions for uniQure. uniQure's average media sentiment score of 0.77 beat Kodiak Sciences' score of 0.54 indicating that uniQure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
1 Very Positive mention(s)
3 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
uniQure
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Kodiak Sciences has a net margin of 0.00% compared to uniQure's net margin of -1,154.84%. uniQure's return on equity of -96.34% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -287.64% -87.83%
uniQure -1,154.84%-96.34%-26.40%

Kodiak Sciences presently has a consensus price target of $109.00, suggesting a potential downside of 1.97%. uniQure has a consensus price target of $56.83, suggesting a potential upside of 138.70%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
uniQure
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75

Summary

uniQure beats Kodiak Sciences on 11 of the 16 factors compared between the two stocks.

How does uniQure compare to Arrowhead Pharmaceuticals?

Arrowhead Pharmaceuticals (NASDAQ:ARWR) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, institutional ownership, profitability, dividends, valuation, analyst recommendations, earnings and media sentiment.

Arrowhead Pharmaceuticals has a net margin of -160.64% compared to uniQure's net margin of -1,154.84%. uniQure's return on equity of -96.34% beat Arrowhead Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Arrowhead Pharmaceuticals-160.64% -172.62% -37.51%
uniQure -1,154.84%-96.34%-26.40%

Arrowhead Pharmaceuticals has a beta of 1.34, meaning that its share price is 34% more volatile than the broader market. Comparatively, uniQure has a beta of 1.14, meaning that its share price is 14% more volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. Comparatively, 78.8% of uniQure shares are owned by institutional investors. 3.6% of Arrowhead Pharmaceuticals shares are owned by insiders. Comparatively, 4.7% of uniQure shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arrowhead Pharmaceuticals currently has a consensus target price of $98.93, indicating a potential upside of 107.05%. uniQure has a consensus target price of $56.83, indicating a potential upside of 138.70%. Given uniQure's stronger consensus rating and higher probable upside, analysts clearly believe uniQure is more favorable than Arrowhead Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
1 Strong Buy rating(s)
2.73
uniQure
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75

uniQure has lower revenue, but higher earnings than Arrowhead Pharmaceuticals. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arrowhead Pharmaceuticals$450.82M14.93-$724.21M-$2.25N/A
uniQure$16.10M103.73-$198.97M-$3.51N/A

In the previous week, Arrowhead Pharmaceuticals had 14 more articles in the media than uniQure. MarketBeat recorded 21 mentions for Arrowhead Pharmaceuticals and 7 mentions for uniQure. uniQure's average media sentiment score of 0.77 beat Arrowhead Pharmaceuticals' score of -0.02 indicating that uniQure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Arrowhead Pharmaceuticals
3 Very Positive mention(s)
4 Positive mention(s)
7 Neutral mention(s)
2 Negative mention(s)
1 Very Negative mention(s)
Neutral
uniQure
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Summary

uniQure beats Arrowhead Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does uniQure compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, dividends, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and earnings.

ImmunityBio has a beta of 0.17, meaning that its stock price is 83% less volatile than the broader market. Comparatively, uniQure has a beta of 1.14, meaning that its stock price is 14% more volatile than the broader market.

In the previous week, ImmunityBio had 29 more articles in the media than uniQure. MarketBeat recorded 36 mentions for ImmunityBio and 7 mentions for uniQure. uniQure's average media sentiment score of 0.77 beat ImmunityBio's score of -0.18 indicating that uniQure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
3 Very Positive mention(s)
2 Positive mention(s)
8 Neutral mention(s)
8 Negative mention(s)
1 Very Negative mention(s)
Neutral
uniQure
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

ImmunityBio has a net margin of -607.79% compared to uniQure's net margin of -1,154.84%. ImmunityBio's return on equity of 0.00% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-607.79% N/A -54.83%
uniQure -1,154.84%-96.34%-26.40%

8.6% of ImmunityBio shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 66.1% of ImmunityBio shares are held by insiders. Comparatively, 4.7% of uniQure shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

ImmunityBio presently has a consensus price target of $16.00, suggesting a potential upside of 165.78%. uniQure has a consensus price target of $56.83, suggesting a potential upside of 138.70%. Given ImmunityBio's higher probable upside, equities research analysts clearly believe ImmunityBio is more favorable than uniQure.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.71
uniQure
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75

uniQure has lower revenue, but higher earnings than ImmunityBio. uniQure is trading at a lower price-to-earnings ratio than ImmunityBio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M56.53-$351.40M-$1.08N/A
uniQure$16.10M103.73-$198.97M-$3.51N/A

Summary

uniQure beats ImmunityBio on 9 of the 17 factors compared between the two stocks.

How does uniQure compare to Ligand Pharmaceuticals?

uniQure (NASDAQ:QURE) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their dividends, institutional ownership, earnings, media sentiment, profitability, analyst recommendations, risk and valuation.

78.8% of uniQure shares are owned by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are owned by institutional investors. 4.7% of uniQure shares are owned by company insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

uniQure has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, indicating that its share price is 16% more volatile than the broader market.

uniQure currently has a consensus target price of $56.83, indicating a potential upside of 138.70%. Ligand Pharmaceuticals has a consensus target price of $355.38, indicating a potential upside of 15.09%. Given uniQure's higher possible upside, equities analysts plainly believe uniQure is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
uniQure
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75
Ligand Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

In the previous week, Ligand Pharmaceuticals had 3 more articles in the media than uniQure. MarketBeat recorded 10 mentions for Ligand Pharmaceuticals and 7 mentions for uniQure. uniQure's average media sentiment score of 0.77 beat Ligand Pharmaceuticals' score of 0.69 indicating that uniQure is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
uniQure
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Ligand Pharmaceuticals
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Ligand Pharmaceuticals has higher revenue and earnings than uniQure. uniQure is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
uniQure$16.10M103.73-$198.97M-$3.51N/A
Ligand Pharmaceuticals$268.09M23.04$124.45M$2.24137.85

Ligand Pharmaceuticals has a net margin of 20.27% compared to uniQure's net margin of -1,154.84%. Ligand Pharmaceuticals' return on equity of 5.22% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
uniQure-1,154.84% -96.34% -26.40%
Ligand Pharmaceuticals 20.27%5.22%2.74%

Summary

Ligand Pharmaceuticals beats uniQure on 12 of the 17 factors compared between the two stocks.

How does uniQure compare to CG Oncology?

CG Oncology (NASDAQ:CGON) and uniQure (NASDAQ:QURE) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

26.6% of CG Oncology shares are held by institutional investors. Comparatively, 78.8% of uniQure shares are held by institutional investors. 4.8% of CG Oncology shares are held by company insiders. Comparatively, 4.7% of uniQure shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CG Oncology has a beta of 0.35, indicating that its share price is 65% less volatile than the broader market. Comparatively, uniQure has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

CG Oncology currently has a consensus target price of $88.11, suggesting a potential upside of 18.43%. uniQure has a consensus target price of $56.83, suggesting a potential upside of 138.70%. Given uniQure's stronger consensus rating and higher probable upside, analysts plainly believe uniQure is more favorable than CG Oncology.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CG Oncology
1 Sell rating(s)
1 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.73
uniQure
1 Sell rating(s)
3 Hold rating(s)
11 Buy rating(s)
1 Strong Buy rating(s)
2.75

In the previous week, CG Oncology had 13 more articles in the media than uniQure. MarketBeat recorded 20 mentions for CG Oncology and 7 mentions for uniQure. uniQure's average media sentiment score of 0.77 beat CG Oncology's score of 0.57 indicating that uniQure is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CG Oncology
4 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
uniQure
2 Very Positive mention(s)
3 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

CG Oncology has higher earnings, but lower revenue than uniQure. CG Oncology is trading at a lower price-to-earnings ratio than uniQure, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CG Oncology$6.17M1,077.74-$160.99M-$2.76N/A
uniQure$16.10M103.73-$198.97M-$3.51N/A

uniQure has a net margin of -1,154.84% compared to CG Oncology's net margin of -3,851.09%. CG Oncology's return on equity of -24.58% beat uniQure's return on equity.

Company Net Margins Return on Equity Return on Assets
CG Oncology-3,851.09% -24.58% -23.40%
uniQure -1,154.84%-96.34%-26.40%

Summary

uniQure beats CG Oncology on 10 of the 17 factors compared between the two stocks.

Get uniQure News Delivered to You Automatically

Sign up to receive the latest news and ratings for QURE and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding QURE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QURE vs. The Competition

MetricuniQureBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.73B$4.15B$7.85B$12.17B
Dividend YieldN/A3.62%2.46%4.41%
P/E RatioN/A26.5532.9127.37
Price / Sales95.3216.058.595.73
Price / CashN/A26.3721.9322.50
Price / Book5.214.074.403.70
Net Income-$198.97M-$22.86M$3.52B$392.17M
7 Day Performance-3.99%-7.26%-5.34%-4.53%
1 Month Performance0.46%-4.96%-3.61%-5.86%
1 Year Performance-26.77%-2.87%0.01%-7.78%

uniQure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QURE
uniQure
3.2027 of 5 stars
$21.88
-8.1%
$56.83
+159.8%
-20.3%$1.73B$16.10MN/A221
KOD
Kodiak Sciences
2.3576 of 5 stars
$111.19
+2.7%
$109.00
-2.0%
+469.9%$6.80BN/AN/A124
ARWR
Arrowhead Pharmaceuticals
2.9457 of 5 stars
$47.78
+1.3%
$98.93
+107.1%
+15.8%$6.64B$450.82MN/A711
IBRX
ImmunityBio
1.7725 of 5 stars
$6.02
-0.8%
$16.00
+165.8%
+189.4%$6.46B$113.29MN/A691
LGND
Ligand Pharmaceuticals
3.7742 of 5 stars
$308.79
-2.4%
$355.38
+15.1%
+53.7%$6.33B$268.09M137.8547

Related Companies and Tools


This page (NASDAQ:QURE) was last updated on 11/16/2026 by MarketBeat.com Staff.
From Our Partners